MIRA

Mira Pharmaceuticals, Inc. (MIRA) | Rumor.io

Mira Pharmaceuticals

MIRA

Attention (50-day avg)0%

Attention rank (50-day avg)#3,128

Bullish sentiment (50-day avg)77%

Price to earnings ratio-0.66

Market capitalization37.9M

Earnings per share-1.22

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-10.4M

Social

What share of all stock conversation is about MIRA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

May 27

MIRA Pharmaceuticals, Inc. has secured worldwide rights for Ketamir-2 across 10 major pharmaceutical markets ahead of planned Phase 2a development in CIPN.
The company has completed positive Phase 1 data for Ketamir-2, with an active IND in place, positioning the asset for important developments.
MIRA is trading above its support zone and has broken above the daily SMA100, with potential upside targets at $0.0948, $0.1017, $0.1085, $0.1182, and $0.1305.

Generated by AI

Sentiment

Of the messages about MIRA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	73.68% -26.32	88.15% +1.54
Bearish	—	—	26.32% +26.32	11.85% -1.54

Bullish· May 17

$MIRA is holding support strong, with a potential nice move up soon.
The company's narrative is huge, with a worldwide big potential, and patience is needed for the long-term upside.
$MIRA is expected to break 1M, with a strong upside push potentially coming soon, driven by its organic and bullish chart.

Bearish· Oct 16

$MIRA is experiencing a mid-afternoon dip in response to strong gains, with some investors trying to buy in at a lower price.
The company's recent acquisition of SKNY through a related-party transaction may be a pump and dump, and the stock could be overvalued.
$MIRA's preclinical stage and lack of IND status may lead to a big fade, with some investors already expecting the stock to go red.

Generated by AI

Topics

Of the messages about MIRA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	50%	16.64%
Technical Analysis	—	—	50%	18.74%
Analysts	—	—	0%	27.95%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0.04%
Macro	—	—	0%	36.63%

Announcements· Oct 24

MIRA Pharmaceuticals initiated a Multiple Ascending Dose (MAD) Phase 1 study of Oral Ketamir-2 for chemotherapy-induced neuropathic pain.
The company selected chemotherapy-induced neuropathic pain as the lead Phase 2a indication for Ketamir-2.
Mira Network's decentralized AI layer uses collective model verification to curb hallucinations, processing up to 2B tokens daily, with $MIRA enabling staking and governance.

Technical Analysis· Oct 16

$MIRA is forming a potential cup and handle pattern, with a target of $3.7-$5.
The stock has bounced off its top resistance line, and is showing a possible technical breakout with massive volume and a jumping RSI.
$MIRA needs to break the pennant and VWAP to continue its upward momentum, with potential targets at $2.45, $2.93, and $3.

Generated by AI

Community

Of the messages about MIRA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	11.76%	12.48%
Newcomers	—	—	88.24%	87.52%

Regulars· Oct 20

The regulars are watching MIRA Pharmaceuticals, Inc. (MIRA) for a potential breakout, as evidenced by the mention of a "small green candle" on Monday.
MIRA is part of a group of stocks that are all up, suggesting a positive trend among these assets, with $ASTER, $XION, $MBG, and $OPEN also showing gains.
The regulars are looking for further upward momentum in MIRA and other stocks, as they believe "we only need to go higher".

Newcomers· Sep 1

MIRA Pharmaceuticals is advancing its non-opioid oral medication MIRA-55, with positive preclinical toxicology results supporting the next steps for IND work.
Newcomers are noticing the high trading volume in MIRA, with some users commenting on the rapid increase in volume and the potential for the stock to break through key resistance levels.
Some users are speculating on the stock's potential, with one user noting the importance of breaking through the 200-day moving average at $1.12, and another user indicating a potential support level at $0.87.

Generated by AI

News

British police say they are investigating allegations anti-immigration party Reform UK broke foreign-donation rules

20d agoBarchart.com

Israel will close the British consulate in Jerusalem in response to UK sanctions on settlements, foreign minister says

21d agoBarchart.com

US job market rebounded in August as employers added a surprising 162,000 jobs; the unemployment rate stayed at 4.1%

25d agoBarchart.com

Ready for Take-off: Air Canada Expands Global Reach with New Routes and Flights to Asia, Europe and Latin America

26d agoBarchart.com

Kyivstar Group Reports Second Quarter 2025 Trading Update

27d agoBarchart.com

Byrna Appoints Matt McBrady to Board of Directors

27d agoBarchart.com

Also Discussed

Investors talking about MIRA also mention

#	Name	Attention
1	Allogene Therapeutics IncALLO	0%new
2	Corgi Total U.S. Market 2x Daily ETFUSX	0%0
3	HUDSON PACIFIC PROPERTIES INCHPP	0%new
4	Crane NXT, Co.CXT	0%0
5	Abrdn Healthcare Opportunities FundTHQ	0.01%new
6	comScore, Inc.SCOR	0%new
7	ELP - Companhia Paranaense de Energia - COPEL	——
8	Humacyte Inc.HUMA	0%0
9	Quanterix CorporationQTRX	0%new
10	MBG By Multibank GroupMBG	0%new

Mira Pharmaceuticals, Inc.

Healthcare
Drug Manufacturers - General

Mira Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapeutics for neurologic, neuropsychiatric, metabolic, and pain-related disorders. The company’s pipeline centers on investigational drug candidates such as Ketamir-2, MIRA-55, and SKNY-1, which are being evaluated for conditions including neuropathic and inflammatory pain, anxiety, cognitive impairment, obesity, addiction-related disorders, and smoking cessation. Mira Pharmaceuticals concentrates on early-stage drug discovery and development, with an emphasis on small-molecule therapies designed to address unmet medical needs across the central nervous system and related treatment areas. The company operates as a specialized developer within the pharmaceutical sector, with its current work centered on advancing experimental treatments rather than commercial products.

Website

Location

1200 Brickell Avenue

Miami, FL, 32183

United States

Social

What share of all stock conversation is about MIRA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

May 27

MIRA Pharmaceuticals, Inc. has secured worldwide rights for Ketamir-2 across 10 major pharmaceutical markets ahead of planned Phase 2a development in CIPN.
The company has completed positive Phase 1 data for Ketamir-2, with an active IND in place, positioning the asset for important developments.
MIRA is trading above its support zone and has broken above the daily SMA100, with potential upside targets at $0.0948, $0.1017, $0.1085, $0.1182, and $0.1305.

Generated by AI

Sentiment

Of the messages about MIRA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	73.68% -26.32	88.15% +1.54
Bearish	—	—	26.32% +26.32	11.85% -1.54

Bullish· May 17

$MIRA is holding support strong, with a potential nice move up soon.
The company's narrative is huge, with a worldwide big potential, and patience is needed for the long-term upside.
$MIRA is expected to break 1M, with a strong upside push potentially coming soon, driven by its organic and bullish chart.

Bearish· Oct 16

$MIRA is experiencing a mid-afternoon dip in response to strong gains, with some investors trying to buy in at a lower price.
The company's recent acquisition of SKNY through a related-party transaction may be a pump and dump, and the stock could be overvalued.
$MIRA's preclinical stage and lack of IND status may lead to a big fade, with some investors already expecting the stock to go red.

Generated by AI

Topics

Of the messages about MIRA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	50%	16.64%
Technical Analysis	—	—	50%	18.74%
Analysts	—	—	0%	27.95%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0.04%
Macro	—	—	0%	36.63%

Announcements· Oct 24

MIRA Pharmaceuticals initiated a Multiple Ascending Dose (MAD) Phase 1 study of Oral Ketamir-2 for chemotherapy-induced neuropathic pain.
The company selected chemotherapy-induced neuropathic pain as the lead Phase 2a indication for Ketamir-2.
Mira Network's decentralized AI layer uses collective model verification to curb hallucinations, processing up to 2B tokens daily, with $MIRA enabling staking and governance.

Technical Analysis· Oct 16

$MIRA is forming a potential cup and handle pattern, with a target of $3.7-$5.
The stock has bounced off its top resistance line, and is showing a possible technical breakout with massive volume and a jumping RSI.
$MIRA needs to break the pennant and VWAP to continue its upward momentum, with potential targets at $2.45, $2.93, and $3.

Generated by AI

Community

Of the messages about MIRA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	11.76%	12.48%
Newcomers	—	—	88.24%	87.52%

Regulars· Oct 20

The regulars are watching MIRA Pharmaceuticals, Inc. (MIRA) for a potential breakout, as evidenced by the mention of a "small green candle" on Monday.
MIRA is part of a group of stocks that are all up, suggesting a positive trend among these assets, with $ASTER, $XION, $MBG, and $OPEN also showing gains.
The regulars are looking for further upward momentum in MIRA and other stocks, as they believe "we only need to go higher".

Newcomers· Sep 1

MIRA Pharmaceuticals is advancing its non-opioid oral medication MIRA-55, with positive preclinical toxicology results supporting the next steps for IND work.
Newcomers are noticing the high trading volume in MIRA, with some users commenting on the rapid increase in volume and the potential for the stock to break through key resistance levels.
Some users are speculating on the stock's potential, with one user noting the importance of breaking through the 200-day moving average at $1.12, and another user indicating a potential support level at $0.87.

Generated by AI

Mira Pharmaceuticals

Social

May 27

Bullish· May 17

Bearish· Oct 16

Announcements· Oct 24

Technical Analysis· Oct 16

Regulars· Oct 20

Newcomers· Sep 1

British police say they are investigating allegations anti-immigration party Reform UK broke foreign-donation rules

Israel will close the British consulate in Jerusalem in response to UK sanctions on settlements, foreign minister says

US job market rebounded in August as employers added a surprising 162,000 jobs; the unemployment rate stayed at 4.1%

Ready for Take-off: Air Canada Expands Global Reach with New Routes and Flights to Asia, Europe and Latin America

Kyivstar Group Reports Second Quarter 2025 Trading Update

Byrna Appoints Matt McBrady to Board of Directors

Also Discussed

Mira Pharmaceuticals, Inc.

Company Information

Location

British police say they are investigating allegations anti-immigration party Reform UK broke foreign-donation rules

Israel will close the British consulate in Jerusalem in response to UK sanctions on settlements, foreign minister says

US job market rebounded in August as employers added a surprising 162,000 jobs; the unemployment rate stayed at 4.1%

Ready for Take-off: Air Canada Expands Global Reach with New Routes and Flights to Asia, Europe and Latin America

Kyivstar Group Reports Second Quarter 2025 Trading Update

Byrna Appoints Matt McBrady to Board of Directors

Also Discussed

Social

May 27

Bullish· May 17

Bearish· Oct 16

Announcements· Oct 24

Technical Analysis· Oct 16

Regulars· Oct 20

Newcomers· Sep 1